LB Pharmaceuticals Inc

LBRX · NasdaqGM · Stock · Healthcare

$34.00

-2.27% today

Delayed price, 2026-10-15 10:20 UTC

What LB Pharmaceuticals does

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.

Key facts

Sector

Healthcare

Industry

Biotechnology

Market cap

$1.10B

P/E (ttm)

340.0

Forward P/E

-6.6

Dividend yield

0.00%

Beta

—

Profit margin

0.0%

Employees

Headquarters

New York, NY, United States

Exchange

NasdaqGM

Website

lbpharma.us

Performance

1 Month

-19.9%

3 Months

+8.2%

6 Months

+11.4%

1 Year

+117.9%

5 Years

+110.8%

$14.3252-week range$50.16

Biggest setback — last 12 months

-31.1%

31 Aug 2026 → 12 Oct 2026

Fell from $49.34 to $34.00 — its sharpest sustained decline this year.

Biggest run-up — last 12 months

+230.9%

10 Nov 2025 → 31 Aug 2026

Ran from $14.91 to $49.34 — its strongest sustained advance this year.

Price outlook — trend & volatility model

● Trend: Above long-term trend

Price sits above its 200-day average, but the shorter-term averages are not cleanly aligned above/below it.

Horizon	Bear case (−1σ)	Base case	Bull case (+1σ)
1 Month	$28.49 (-16.2%)	$34.00	$40.58 (+19.4%)
3 Months	$25.02 (-26.4%)	$34.00	$46.20 (+35.9%)
6 Months	$22.04 (-35.2%)	$34.00	$52.45 (+54.3%)
12 Months	$18.42 (-45.8%)	$34.00	$62.77 (+84.6%)

Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 61.3%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Amphastar Pharmaceuticals, Inc.

$26.08 · +0.1%

YARW

Yarrow Bioscience Inc

Recent headlines

LB Pharmaceuticals (LBRX) Stock Fair Value Rises As LB 102 Outlook Shifts — Simply Wall St.2 Reasons LB Pharmaceuticals (LBRX) Looks Pricey Following Its CFO Appointment — Simply Wall St.

Recent insider activity

Acquired 286,205 shares at $34.94 — Deep Track Biotechnology Master Fund, Ltd., 10% Owner · 2026-08-03

Source: SEC Form 4 filings. An "acquired" entry with no price is typically a stock award or option exercise rather than an open-market purchase. Search all insider trades →

Learn the basics

What is a stock? Understanding risk and reward Why diversification matters

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.